{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T03:56:47Z","timestamp":1776398207581,"version":"3.51.2"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T00:00:00Z","timestamp":1723593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Astra Zeneca"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Anti-Ro60 and anti-Ro52 autoantibodies are frequently used as diagnostic biomarkers for Sj\u00f6gren\u2019s disease, but their clinical significance in systemic lupus erythematosus (SLE) is not well characterized.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients fulfilling SLE classification criteria were studied according to their anti-Ro status. We defined Ro positivity (Ro+) as those who have either anti-Ro60 or anti-Ro52 positivity. Patient characteristics and disease outcomes, including High Disease Activity Status (HDAS) defined as an ever attainment of SLEDAI2K \u226510, adjusted mean SLEDAI (AMS), and time-adjusted mean clinical SLEDAI (excluding serologic activities) were compared using linear or logistic regressions. Furthermore, isolated or dual positivity of anti-Ro60 and anti-Ro52 were studied.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Out of 409 patients, 47.2% were Ro+. Ro+ patients were predominantly Asian, had positive dsDNA and hypocomplementemia. They showed a higher likelihood of HDAS (OR 1.65, 95% CI 1.10\u20132.48, P\u2009=\u20090.015), AMS\u2009&amp;gt;4 (OR 1.84, 1.18\u20132.88, P\u2009=\u20090.007) and more frequent use of glucocorticoids (OR 1.87, 1.16\u20133.03, P\u2009=\u20090.011) and immunosuppressants (OR 2.0, 1.26\u20133.17, P\u2009=\u20090.003). Additionally, 24.4% of Ro+ patients experienced sicca symptoms, and hypergammaglobulinemia was significantly more common. Multivariate analysis confirmed that Asian ethnicity, severe flares, AMS, hypocomplementemia, rheumatoid factor, proteinuria, leucopenia and sicca symptoms were significantly linked to Ro positivity.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Anti-Ro positivity is associated with higher disease activity and increased treatment needs. Ro positivity correlates with laboratory abnormalities such as hypocomplementemia and leucopenia. These findings highlight the importance of anti-Ro60\/Ro52 testing in the clinical evaluation of SLE.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keae362","type":"journal-article","created":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T16:53:42Z","timestamp":1723654422000},"page":"1923-1929","source":"Crossref","is-referenced-by-count":6,"title":["The implication of anti-Ro60 with or without anti-Ro52 antibody in patients with systemic lupus erythematosus"],"prefix":"10.1093","volume":"64","author":[{"given":"Katie","family":"Liao","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Monash Health , Clayton, VIC,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning","family":"Li","sequence":"additional","affiliation":[{"name":"Centre for Inflammatory Diseases, School of Clinical Sciences, Monash University , Clayton, VIC,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Bonin","sequence":"additional","affiliation":[{"name":"Centre for Inflammatory Diseases, School of Clinical Sciences, Monash University , Clayton, VIC,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Koelmeyer","sequence":"additional","affiliation":[{"name":"Centre for Inflammatory Diseases, School of Clinical Sciences, Monash University , Clayton, VIC,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna","family":"Kent","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Monash Health , Clayton, VIC,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Pellicano","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Monash Health , Clayton, VIC,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thilinie","family":"De Silva","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Monash Health , Clayton, VIC,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristy","family":"Yap","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Monash Health , Clayton, VIC,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5691-4344","authenticated-orcid":false,"given":"Vera","family":"Golder","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Monash Health , Clayton, VIC,","place":["Australia"]},{"name":"Centre for Inflammatory Diseases, School of Clinical Sciences, Monash University , Clayton, VIC,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2713-2391","authenticated-orcid":false,"given":"A Richard","family":"Kitching","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Monash Health , Clayton, VIC,","place":["Australia"]},{"name":"Centre for Inflammatory Diseases, School of Clinical Sciences, Monash University , Clayton, VIC,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9507-3338","authenticated-orcid":false,"given":"Eric F","family":"Morand","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Monash Health , Clayton, VIC,","place":["Australia"]},{"name":"Centre for Inflammatory Diseases, School of Clinical Sciences, Monash University , Clayton, VIC,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9416-7383","authenticated-orcid":false,"given":"Alberta","family":"Hoi","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Monash Health , Clayton, VIC,","place":["Australia"]},{"name":"Centre for Inflammatory Diseases, School of Clinical Sciences, Monash University , Clayton, VIC,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,8,14]]},"reference":[{"key":"2025040212104404800_keae362-B1","doi-asserted-by":"crossref","first-page":"606195","DOI":"10.1155\/2012\/606195","article-title":"Clinical and pathological roles of Ro\/SSA autoantibody system","volume":"2012","author":"Yoshimi","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"2025040212104404800_keae362-B2","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1136\/ard.61.6.554","article-title":"Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group","volume":"61","author":"Vitali","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"2025040212104404800_keae362-B3","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/anr.1780320213","article-title":"Correlation of anti-Ro antibody with photosensitivity rash in systemic lupus erythematosus patients","volume":"32","author":"Mond","year":"1989","journal-title":"Arthritis Rheum"},{"key":"2025040212104404800_keae362-B4","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s10067-008-1043-5","article-title":"Anti-Ro antibody and cutaneous vasculitis in systemic lupus erythematosus","volume":"28","author":"Fukuda","year":"2009","journal-title":"Clin Rheumatol"},{"key":"2025040212104404800_keae362-B5","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/RHU.0b013e31823ecbdf","article-title":"Systemic lupus erythematosus with Sjogren syndrome compared to systemic lupus erythematosus alone: a meta-analysis","volume":"18","author":"Yao","year":"2012","journal-title":"J Clin Rheumatol"},{"key":"2025040212104404800_keae362-B6","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1177\/096120339700600205","article-title":"Anti-Ro(SS-A) antibody positive Sjogren's\/lupus erythematosus overlap syndrome","volume":"6","author":"Provost","year":"1997","journal-title":"Lupus"},{"key":"2025040212104404800_keae362-B7","doi-asserted-by":"crossref","first-page":"865","DOI":"10.3899\/jrheum.190250","article-title":"Sjogren syndrome in systemic lupus erythematosus: a subset characterized by a systemic inflammatory state","volume":"47","author":"Ruacho","year":"2020","journal-title":"J Rheumatol"},{"key":"2025040212104404800_keae362-B8","doi-asserted-by":"crossref","first-page":"194","DOI":"10.5694\/mja16.01282","article-title":"The Australian Lupus Registry and Biobank: a timely initiative","volume":"206","author":"O'Neill","year":"2017","journal-title":"Med J Aust"},{"key":"2025040212104404800_keae362-B9","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/art.1780400928","article-title":"Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus","volume":"40","author":"Hochberg","year":"1997","journal-title":"Arthritis Rheum"},{"key":"2025040212104404800_keae362-B10","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1002\/art.34473","article-title":"Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus","volume":"64","author":"Petri","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2025040212104404800_keae362-B11","author":"Bureau of Statistics","year":"2019"},{"key":"2025040212104404800_keae362-B12","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/0961203309346505","article-title":"SLEDAI-2K for a 30-day window","volume":"19","author":"Touma","year":"2010","journal-title":"Lupus"},{"key":"2025040212104404800_keae362-B13","doi-asserted-by":"crossref","first-page":"953","DOI":"10.7326\/0003-4819-142-12_Part_1-200506210-00004","article-title":"The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial","volume":"142","author":"Buyon","year":"2005","journal-title":"Ann Intern Med"},{"key":"2025040212104404800_keae362-B14","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2019-000372","article-title":"High disease activity status suggests more severe disease and damage accrual in systemic lupus erythematosus","volume":"7","author":"Koelmeyer","year":"2020","journal-title":"Lupus Sci Med"},{"key":"2025040212104404800_keae362-B15","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/art.1780390303","article-title":"The development and initial validation of the Systemic Lupus International Collaborating Clinics\/American College of Rheumatology damage index for systemic lupus erythematosus","volume":"39","author":"Gladman","year":"1996","journal-title":"Arthritis Rheum"},{"key":"2025040212104404800_keae362-B16","first-page":"1977","article-title":"Summarizing disease features over time: i. Adjusted mean SLEDAI derivation and application to an index of disease activity in lupus","volume":"30","author":"Ibanez","year":"2003","journal-title":"J Rheumatol"},{"key":"2025040212104404800_keae362-B17","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1136\/annrheumdis-2015-207726","article-title":"Definition and initial validation of a Lupus Low Disease Activity State (LLDAS)","volume":"75","author":"Franklyn","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2025040212104404800_keae362-B18","doi-asserted-by":"crossref","first-page":"e22965","DOI":"10.1002\/jcla.22965","article-title":"Epidemiological survey of antinuclear antibodies in healthy population and analysis of clinical characteristics of positive population","volume":"33","author":"Li","year":"2019","journal-title":"J Clin Lab Anal"},{"key":"2025040212104404800_keae362-B19","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1002\/art.21414","article-title":"Is antibody clustering predictive of clinical subsets and damage in systemic lupus erythematosus?","volume":"52","author":"To","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2025040212104404800_keae362-B20","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/03009742.2017.1324909","article-title":"Systematic review and meta-analysis of the epidemiology of polyautoimmunity in Sjogren's syndrome (secondary Sjogren's syndrome) focusing on autoimmune rheumatic diseases","volume":"47","author":"Alani","year":"2018","journal-title":"Scand J Rheumatol"},{"key":"2025040212104404800_keae362-B21","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.rdc.2016.03.002","article-title":"Autoantibodies in Sjogren's Syndrome","volume":"42","author":"Fayyaz","year":"2016","journal-title":"Rheum Dis Clin North Am"},{"key":"2025040212104404800_keae362-B22","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1002\/art.42243","article-title":"Machine learning for the identification of a common signature for anti-SSA\/Ro 60 antibody expression across autoimmune diseases","volume":"74","author":"Foulquier","year":"2022","journal-title":"Arthritis Rheumatol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keae362\/58856524\/keae362.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/4\/1923\/58856524\/keae362.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/4\/1923\/58856524\/keae362.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T16:42:37Z","timestamp":1743612157000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/4\/1923\/7733587"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,14]]},"references-count":22,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,8,14]]},"published-print":{"date-parts":[[2025,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keae362","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2024,8,14]]}}}